Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2014

View Archived Issues

Structure-based discovery of novel ITK inhibitors, GNE-9822 lead identified

A potent mGluR5 PAM shows promise in rodent cognition models

Results of a phase I dose-escalation study of a chikungunya virus vaccine

VX-787, first-in-class PB2 influenza polymerase inhibitor

arGEN-X reports preclinical data for ARGX-113

Glenmark Pharmaceuticals to begin IND-enabling studies of new bispecific antibody

Bristol-Myers Squibb and Celgene to evaluate immunotherapy/chemotherapy combination

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Pfizer and Crohn's & Colitis Foundation of America form IBD collaboration

Aeolus files IND for acute radiation syndrome candidate AEOL-10150

Illumina forms multiple collaborations for oncology genomics analysis

AM-9514, a GK activator with good pharmacokinetic profile in vivo

KalVista Pharmaceuticals confirms first-in-human trial of KVD-001

Potential AD treatment activates TGF-beta signaling pathway in the brain

Vertex Pharmaceuticals patents novel sodium channel blockers

Toyama designs novel antifungal agents

Researchers at Bayer Schering Pharma synthesize new products for cancer

Hanmi Pharm enters into agreement with Luye Pharma Group for poziotinib

Korean scientists present new anti-C5 MAbs

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Baxter's PEGylated rFVIII meets primary endpoint in phase III trial

Apixaban granted FDA approval for DVT and PE

EMA accepts Basilea Pharmaceutica's isavuconazole MAA for review

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

GSK to conduct phase II study of GSK-2862277 to prevent acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...